Dr. Eradat on Novel Therapy Vs Chemotherapy in CLL

Video

Herbert A. Eradat, MD, compares novel therapies with cytotoxic chemotherapy in the treatment of patients with chronic lymphocytic leukemia.

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, compares novel therapies with cytotoxic chemotherapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

CLL develops through 2 pathogenic mechanisms: one is that cells either do not die properly, or the cells are dependent on signals through the B-cell receptor, Eradat explains. Most novel therapies exploit those 2 pathogenic mechanisms, which is why they tend to be more effective and better tolerated than cytotoxic chemotherapy, according to Eradat.

With novel therapies, agents are attacking how the disease develops and thrives in the patient, whereas traditional cytotoxic chemotherapy is controlled administration of a poison that is supposed to control the disease, but is significantly toxic, concludes Eradat.

Related Videos
Ilyas Sahin, MD
Raj Singh, MD
Saad J. Kenderian, MB, CHB
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Joseph Mikhael, MD
Michael Richardson, MD